Close Menu

A Giacometti

A Reduction Grade of Lipodystrophy and Limited Side Effects after HAART Regimen with Raltegravir, Lamivudine, Darunavir and Ritonavir in an HIV-1 Infected Patient after Six Years of Antiretroviral Therapy

Issue: 
DOI: 
10.7727/wimj.2014.066
Pages: 
291–3

ABSTRACT

Accepted: 
14 Apr, 2015
PDF Attachment: 
Journal Sections: 
e-Published: 14 Jul, 2015

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation

Issue: 
DOI: 
10.7727/wimj.2013.264
Pages: 
779–84

ABSTRACT

Accepted: 
28 Nov, 2013
PDF Attachment: 
Journal Sections: 
e-Published: 03 Sep, 2014

Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation

Issue: 
DOI: 
10.7727/wimj.2014.068
Pages: 
785–7
 
INTRODUCTION
 
Maraviroc, originally designated UK-427857, is a small molecule and the first oral antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. This drug, classed as an entry inhibitor, was developed by the drug company Pfizer in its United Kingdom laboratory located in Sandwich. 
 
Accepted: 
27 Mar, 2014
PDF Attachment: 
Journal Sections: 
e-Published: 29 Aug, 2014

Sustained Increase of Serum Creatine Phosphokinase Levels and Progressive Muscle Abnormalities Associated with Raltegravir Use during 32-week Follow-up in an HIV-1 Experienced Patient on Simplified HAART Regimen, Intolerant to PIs and Abacavir: A Case Rep

Issue: 
DOI: 
10.7727/wimj. 2011.193
Pages: 
377–9

ABSTRACT


Sustained increase of serum creatine phosphokinase (CPK) concentrations and muscle abnormalities have been reported in patients taking raltegravir (RAL). In this report, we describe a case of sustained and asymptomatic increase of serum CPK concentrations associated with raltegravir, zidovudine, and lamivudine in an HIV-1 experienced patient with intolerance to protease inhibitor, abacavir and pencillin during 32 weeks of continuous drug monitoring.

PDF Attachment: 
Journal Sections: 
e-Published: 14 Aug, 2013
Subscribe to RSS - A Giacometti
Top of Page